DelgadoSV, SaldañaSN, BarzmanDH, CoffeyB. Response to duloxetine in a depressed, treatment-resistant adolescent female. J Child Adolesc Psychopharmacol, 17:889–894. 2007.
2.
Eli Lilly and Company. Duloxetine Package Insert. 2009.
3.
GuyW. ECDEU Assessment Manual for Psychopharmacology, Revised. Rockville, MD: US Department of Health, Education and Welfare, 1976.
4.
LacyCF, ArmstrongLL, GoldmanMP, LanceLL. Drug Information Handbook: A Comprehensive Resource for all Clinicians and Healthcare Professionals. 15th. Hudson, OH: Lexi-Comp, 2007.
5.
Lilly Research Laboratories. Data on File. 2010.
6.
MarchJS, EmslieGJ, KratochvilCJ, PangalloBA, LoboE, TamuraRN, KogutS, QuinlanT, PrakashA. An open-label study of tolerability, safety, pharmacokinetics of duloxetine in children (7–11 years), adolescents (12–17 years) with major depression. NCDEU, Hollywood: Florida, 2009.
7.
PoznanskiEO, CookSC, CarrollBJ. A depression rating scale for children. Pediatrics, 64:442–450. 1979.
8.
RavinKA, RappaportLD, ZuckerbraunNS, WadowskyRM, WaldER, MichaelsMM. Mycoplasma pneumoniae and atypical Stevens-Johnson syndrome: A case series. Pediatrics, 119:e1002–e1005. 2007.
9.
SheehanDV, SheehanKH, ShytleRD, JanavsJ, BannonY, RogersJE, MiloKM, StockSL, WilkinsonB. Reliability and validity of the Mini International Neuropsychiatric Interview for Children and Adolescents (MINI-KID)J Clin Psychiatry, 71:313–326. 2010.
